Acute Myeloid Leukemia (AML) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Acute myeloid leukemia (AML) is a cancer of the stem cells that give rise to the myeloid lineage (red blood cells, platelets, and white blood cells other than B and T cells). Genetic changes that result in neoplastic changes and clonal proliferation, like in other malignancies, are the cause of this condition. Acute myeloid leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are suppressed at an early stage of development. The global incidence of AML will increase from 105,842 cases in 2019 to 119,247 cases in 2030, with a potential growth rate of 1.09% during the forecast period. By 2030, the incidence of diagnosed acute myelogenous leukemia (AML) in the United States will increase to 21,530 cases. Likewise, the number of AML cases diagnosed in the EU will increase to 17,139 in 2030. The global incidence of AML will increase from 105,842 cases in 2019 to 119,247 cases in 2030, with a potential growth rate of 1.09% during the forecast period. A variety of chemotherapy regimens, biologic drugs, and stem cell transplantation are available as treatments for acute myeloid leukemia (AML). Fewer than half of AML patients are currently cured by current standard chemotherapy regimens. As a result, all patients ought to be assessed before being accepted into carefully planned clinical trials.

Description

Acute myeloid leukemia (AML) is a cancer of the stem cells that give rise to the myeloid lineage (red blood cells, platelets, and white blood cells other than B and T cells). Genetic changes that result in neoplastic changes and clonal proliferation, like in other malignancies, are the cause of this condition. Acute myeloid leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are suppressed at an early stage of development. Most acute myeloid leukemia (AML) subtypes are distinguished from other related blood disorders by the presence of more than 20% myeloid blasts. The pathophysiology of AML is underpinned by the early development of myeloid cells being stopped from maturing. Acute myelogenous leukemia (AML) is caused by a variety of factors, including preexisting blood disorders, familial syndromes, exposure to the environment, and drug use. However, most patients with newly diagnosed AML have no particular risk factors. Acute myeloid leukemia (AML) patients experience symptoms as a result of either bone marrow failure, leukemia cells invading the organs, or both. Blood tests, bone marrow aspiration and biopsy, which is the gold standard for diagnosing AML, as well as the examination of genetic anomalies are all part of the investigation process.

Acute Myeloid Leukemia (AML)- (Epidemiology)

Diagnoses of AML are more frequently made in developed nations, and white people are more likely to develop it than other populations. With advancing years, AML is more common. The average age of onset is around 70 years old. All age groups are, however, impacted by AML. Men are more likely than women to have AML, particularly in older patients. This is probably because advanced MDS frequently develops into AML, and MDS is more prevalent in men. Manhood-specific occupational exposures have been suggested as a potential explanation for the higher prevalence of AML in men. According to the ACS, there will be 11,310 AML-related deaths in the US in 2023. 4870 women and 6440 men are anticipated to experience these. 20,380 new cases of AML are anticipated in the United States in 2023, according to the American Cancer Society (ACS) (11,410 in men and 8970 in women).

Acute Myeloid Leukemia (AML)- Current Market Size & Forecast Trends

The global AML market was estimated at $3.4 billion in 2024. The approval of targeted therapies like FLT3 inhibitors (gilteritinib) and IDH inhibitors, combined with the increasing use of combination therapies, is driving this segment. AML therapeutics are projected to grow at a CAGR of ~10% through 2035, fueled by the growing aging population and high unmet clinical needs.

A variety of chemotherapy regimens, biologic drugs, and stem cell transplantation are available as treatments for acute myeloid leukemia (AML). Fewer than half of AML patients are currently cured by current standard chemotherapy regimens. As a result, all patients ought to be assessed before being accepted into carefully planned clinical trials. Patients may receive standard therapy if there is no clinical trial available for them. Readmission is necessary for chemotherapy consolidation or to manage the toxic effects of chemotherapy. Patients receiving chemotherapy should avoid crowds and contact with contagious individuals, particularly young children who may have viral infections. Broad-spectrum antibiotics should be administered right away to any patient who exhibits symptoms of neutropenic fever or infection. AML patients must receive appropriate transfusion support. In accordance with the patient's blood test results and bleeding history, this may involve the transfusion of platelets and clotting factors (fresh frozen plasma [FFP], cryoprecipitate). To avoid graft versus host disease (GVHD), blood products must be radioactively treated.

Report Highlights

Acute Myeloid Leukemia (AML)- Current Market Trends

Acute Myeloid Leukemia (AML)- Current & Forecasted Cases across the G8 Countries

Acute Myeloid Leukemia (AML)- Market Opportunities and Sales Potential for Agents

Acute Myeloid Leukemia (AML)- Patient-based Market Forecast to 2035

Acute Myeloid Leukemia (AML)- Untapped Business Opportunities

Acute Myeloid Leukemia (AML)- Product Positioning Vis-a-vis Competitors' Products

Acute Myeloid Leukemia (AML)- KOLs Insight